RSS   Newsletter   Contact   Advertise with us
Post Online Media

Pfenex appoints Evert Schimmelpennink as CEO

Evert SchimmelpenninkAugust 4, 2017, San Diego, Ca., USA - Pfenex, a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, appoints Evert Schimmelpennink as chief executive officer, president, and secretary.
Mr. Schimmelpennink was also appointed to serve as a Class III member of the board of directors effective August 3, 2017.

Mr. Schimmelpennink brings to Pfenex a broad base of biotechnology and pharmaceutical experience with strategic and functional expertise across corporate development, commercial operations, manufacturing and R&D.

Prior to joining Pfenex, he served as the Chief Executive Officer of Alvotech, a biosimilar development company, Vice President Global Injectables at Pfizer and Vice President – Global Generics of Hospira.

Mr. Schimmelpennink received a Masters in bioprocess engineering from the Wageningen University in the Netherlands.




POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.